| Literature DB >> 26055392 |
Kimberly C Claeys1, Abdalhamid M Lagnf, Trishna B Patel, Manu G Jacob, Susan L Davis, Michael J Rybak.
Abstract
INTRODUCTION: Acute bacterial skin and skin structure infections (ABSSSIs) are frequently treated in emergency departments (EDs) or observation units (OUs) initially with intravenous (IV) antibiotics before discharge on oral therapy. This study aims to describe ABSSSI patients discharged directly from EDs/OUs.Entities:
Year: 2015 PMID: 26055392 PMCID: PMC4471063 DOI: 10.1007/s40121-015-0069-7
Source DB: PubMed Journal: Infect Dis Ther ISSN: 2193-6382
Fig. 1Clinical Resource Efficiency Support Team (CREST) Classification and Standardized Early Warning System (SEWS) Score (adapted from [1, 18, 23])
Fig. 2Study Consolidated Standards of Reporting Trials (CONSORT)
Demographics by setting of care
| Characteristics | Emergency department ( | Observation unit ( |
|
|---|---|---|---|
| Age, median (IRQ) | 41 (28–50) | 46 (33–55) | 0.083a |
| Male sex | 121 (55.3) | 42 (47.2) | 0.143 |
| Charlson score, median (IQR) | 1 (0–2) | 1 (0–2) | 0.539a |
| Comorbidities | |||
| Diabetes mellitus | 31 (14.2) | 19 (21.3) | 0.121 |
| Obesity (BMI ≥30 kg/m2) | 23 (10.5) | 17 (19.1) | 0.042 |
| Chronic kidney disease | 12 (5.5) | 1 (1.1) | 0.118b |
| Liver disease | 5 (2.3) | 5 (5.6) | 0.159b |
| COPD/asthma | 16 (7.3) | 16 (18.0) | 0.005 |
| Injection drug use | 23 (10.5) | 11 (12.4) | 0.637 |
| Peripheral vascular disease | 6 (2.7) | 0 (0.0) | 0.115b |
| Prior MRSA infection | 4 (1.8) | 3 (3.4) | 0.410b |
| Prior history of ABSSSI | 42 (19.2) | 23 (25.8) | 0.194 |
| Prior hospitalization, 180 days | 15 (6.8) | 10 (11.2) | 0.201 |
| Prior antibiotics, 90 days | 30 (13.7) | 20 (22.5) | 0.058 |
| Primary location of ABSSSI | 0.004 | ||
| Head/neck | 48 (21.9) | 6 (6.7) | 0.001 |
| Hand | 18 (8.2) | 13 (14.6) | 0.091 |
| Arm | 37 (16.9) | 18 (20.2) | 0.489 |
| Leg | 35 (16.0) | 26 (29.2) | 0.008 |
| Foot | 14 (6.4) | 6 (6.7) | 0.910 |
| Trunk/buttocks | 65 (29.7) | 20 (22.5) | 0.200 |
| SIRS at presentation | |||
| Fever (temperature ≥38.0 °C) | 46 (21.0) | 23 (25.8) | 0.356 |
| WBC >11,000 or <4000 | 15 (6.8) | 15 (16.9) | 0.007 |
| Heart rate ≥90 beats/min | 84 (38.4) | 53 (59.6) | 0.001 |
| Respiratory rate ≥ 20/min | 5 (2.3) | 9 (10.1) | 0.003b |
| Insurance type | |||
| Medicaid | 64 (29.2) | 32 (36.0) | 0.248 |
| Medicare | 26 (11.9) | 7 (7.9) | 0.303 |
| Private | 38 (17.4) | 18 (20.2) | 0.553 |
| None | 81 (37.0) | 23 (25.8) | 0.061 |
ABSSSI acute bacterial skin and skin structure infection, BMI body mass index, COPD chronic obstructive pulmonary disease, IQR interquartile range, MRSA methicillin-resistant Staphylococcus aureus, WBC white blood cell count
aWilcoxon rank sum test
bFisher’s exact test
Antimicrobial therapy by setting of care (emergency department versus observation unit)
| Antibiotic | Emergency department ( | Observation unit ( |
|
|---|---|---|---|
| Empiric IV therapy | |||
| Empiric vancomycin | 31 (14.2) | 35 (39.3) | <0.001 |
| Empiric clindamycin | 128 (58.4) | 26 (29.2) | <0.001 |
| Empiric ampicillin/sulbactam | 37 (16.9) | 19 (21.3) | 0.415 |
| Discharge antibiotic | |||
| Amoxicillin/clavulanate | 19 (8.7) | 12 (13.4) | 0.214 |
| Cephalexin | 41 (18.7) | 7 (7.8) | 0.049 |
| Clindamycin | 106 (48.4) | 30 (33.7) | 0.027 |
| Doxycycline | 8 (3.7) | 1 (1.1) | 0.455b |
| Linezolid | 1 (0.5) | 1 (1.1) | 0.495b |
| None | 16 (7.3) | 18 (20.2) | 0.002 |
| TMP/SMX | 17 (7.8) | 22 (24.7) | <0.001 |
| Dual therapya | 36 (16.4) | 8 (9.0) | 0.107 |
CAMRSA community acquired methicillin-resistant Staphylococcus aureus, IV intravenous, TMP/SMX trimethoprim–sulfamethoxazole
aCoverage of CAMRSA and streptococcal species
bFisher’s exact test
Univariate analysis of 96-h revisit or hospital admission
| Characteristics | 96 h revisit ( | No revisit ( |
|
|---|---|---|---|
| ED setting of care | 23 (76.7) | 19 (70.5) | 0.479 |
| CREST/Eron class II | 8 (26.7) | 57 (20.5) | 0.701 |
| Comorbid conditions | |||
| Diabetes | 6 (20.0) | 44 (15.8) | 0.566 |
| Prior ABSSSI | 12 (40.0) | 53 (19.1) | 0.008 |
| Prior MRSA infection | 3 (10.0) | 4 (1.4) | 0.003a |
| Morbid obesity | 6 (20.0) | 34 (12.2) | 0.250 |
| Charlson comorbidity score (IQR) | 1.0 (0.0–1.3) | 1.0 (0.0–2.0) | 0.601 |
| Surgical intervention | 12 (40.0) | 137 (49.3) | 0.345 |
| Antibiotics 90 Days | 3 (10.0) | 47 (16.9) | 0.382 |
| SIRS criteria on presentation | |||
| Body temp >38 or <36 | 11 (36.7) | 28 (20.9) | 0.049 |
| HR >90 beats/min | 14 (46.7) | 123 (44.2) | 0.800 |
| RR >20 breaths/min | 1 (3.3) | 13 (4.7) | 1.000a |
| WBC >12,000 or <4000 | 4 (13.3) | 26 (9.4) | 0.485 |
| Site of infection | |||
| Arm | 3 (10.0) | 52 (18.7) | 0.319a |
| Leg | 7 (23.3) | 54 (19.4) | 0.631 |
| Head/neck | 3 (10.0) | 51 (18.3) | 0.320 |
| Buttocks/torso | 13(43.3) | 72 (25.9) | 0.042 |
| Hand | 1 (3.3) | 30 (10.8) | 0.197a |
| Foot | 3 (10.0) | 17 (6.1) | 0.427a |
| Type of ABSSSI | |||
| Complicated cellulitis | 3 (10.0) | 35 (12.6) | 0.682a |
| Complicated abscess | 6 (20.0) | 57 (20.5) | 0.948 |
| Uncomplicated cellulitis | 9 (30.0) | 77 (27.7) | 0.789 |
| Uncomplicated abscess | 11 (36.7) | 88 (31.7) | 0.577 |
| Empiric antibiotics | |||
| Ampicillin/sulbactam | 3 (10.0) | 53 (19.1) | 0.319a |
| Discharge antibiotics | |||
| Combination therapy | 6 (20.0) | 38 (13.7) | 0.408 |
| Tissue culture available | 6 (20.0) | 49 (17.6) | 0.802 |
ABSSSI acute bacterial skin and skin structure infection, CREST Clinical Resource Efficiency Support Team, HR heart rate, IQR interquartile range, MRSA methicillin-resistant Staphylococcus aureus, RR respiratory rate, WBC white blood cell
aFisher’s exact test
Multivariable regression analysis of risk factors for 96-h ED revisit or hospital admission
| Factor | Unadjusted OR | 95% CI |
| Adjusted OR | 95% CI |
|
|---|---|---|---|---|---|---|
| Prior ABSSSI | 2.83 | 1.29–6.23 | 0.013 | 2.38 | 1.26–6.35 | 0.014 |
| Prior MRSA | 7.61 | 1.62–35.79 | 0.020 | 4.38 | 0.80–24.20 | 0.072 |
| Temperature >38 or <36 °C | 2.19 | 0.99–4.87 | 0.061 | 2.20 | 0.97–5.00 | 0.059 |
| Location Torso/Buttocks | 2.19 | 1.01–4.73 | 0.042 | 2.36 | 1.07–5.20 | 0.038 |
ABSSSI acute bacterial skin and skin structure infection, CI confidence interval, OR odds ratio, MRSA methicillin-resistant Staphylococcus aureus